Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistDream Pharmacy 24/7 Enterprises Limited 2018 operated websites selling unapproved and misbranded opioid and benzodiazepine drug products in violation of the Federal Food, Drug, and Cosmetic Act sections 301(a), 301(d), 301(k), 503(b), and 505(a). The company introduced these controlled substances into interstate commerce without FDA approval and without proper labeling, creating significant public health risks given the ongoing opioid epidemic and the substantial harms associated with nonmedical benzodiazepine use, particularly when combined with other substances. The FDA identified these violations through review of the company's websites at www.premier-dream.com and www.eirmed360.com.